| Yunus Emre Tarhan, MD | |
|
6201 Harry Hines Blvd, Dallas, TX 75390-5400 | |
| (214) 633-5555 | |
| Not Available |
| Full Name | Yunus Emre Tarhan |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 10 Years |
| Location | 6201 Harry Hines Blvd, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699295196 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | U4949 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Shore Medical Center - | Salem, MA | Hospital |
| Umass Memorial Healthcare-marlborough Hospital | Marlborough, MA | Hospital |
| Ut Southwestern University Hospital - William P. Clements Jr. | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Marlborough Hospitalist Group Pllc | 1254793888 | 34 |
| North Shore Physicians Group Inc | 3577467224 | 488 |
News Archive
By choosing U.S. Representative Paul Ryan as his running mate, Mitt Romney has added some verve to what had been a tedious presidential contest. ... Now we have the potential at least for a true contest of ideas: What is the optimum size and role of government? What is the best way to reduce trillion-dollar annual deficits and $15 trillion in total debt? With a rapidly graying population and entitlements that eat up most of the federal budget, can Medicare's growth be stopped without impoverishing senior citizens? Is it time to raise taxes, even on the middle class?
An injury potential is the direct current potential difference between the site of spinal cord injury and the healthy nerves. Its initial amplitude is a significant indicator of the severity of spinal cord injury.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.
At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
› Verified 3 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194765438 PECOS PAC ID: 4486567104 Enrollment ID: O20031204000918 |
News Archive
By choosing U.S. Representative Paul Ryan as his running mate, Mitt Romney has added some verve to what had been a tedious presidential contest. ... Now we have the potential at least for a true contest of ideas: What is the optimum size and role of government? What is the best way to reduce trillion-dollar annual deficits and $15 trillion in total debt? With a rapidly graying population and entitlements that eat up most of the federal budget, can Medicare's growth be stopped without impoverishing senior citizens? Is it time to raise taxes, even on the middle class?
An injury potential is the direct current potential difference between the site of spinal cord injury and the healthy nerves. Its initial amplitude is a significant indicator of the severity of spinal cord injury.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.
At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
› Verified 3 days ago
| Entity Name | Beth Israel Deaconess Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548202641 PECOS PAC ID: 8123936119 Enrollment ID: O20041001000827 |
News Archive
By choosing U.S. Representative Paul Ryan as his running mate, Mitt Romney has added some verve to what had been a tedious presidential contest. ... Now we have the potential at least for a true contest of ideas: What is the optimum size and role of government? What is the best way to reduce trillion-dollar annual deficits and $15 trillion in total debt? With a rapidly graying population and entitlements that eat up most of the federal budget, can Medicare's growth be stopped without impoverishing senior citizens? Is it time to raise taxes, even on the middle class?
An injury potential is the direct current potential difference between the site of spinal cord injury and the healthy nerves. Its initial amplitude is a significant indicator of the severity of spinal cord injury.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.
At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
› Verified 3 days ago
| Entity Name | North Shore Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588606123 PECOS PAC ID: 3577467224 Enrollment ID: O20050429000668 |
News Archive
By choosing U.S. Representative Paul Ryan as his running mate, Mitt Romney has added some verve to what had been a tedious presidential contest. ... Now we have the potential at least for a true contest of ideas: What is the optimum size and role of government? What is the best way to reduce trillion-dollar annual deficits and $15 trillion in total debt? With a rapidly graying population and entitlements that eat up most of the federal budget, can Medicare's growth be stopped without impoverishing senior citizens? Is it time to raise taxes, even on the middle class?
An injury potential is the direct current potential difference between the site of spinal cord injury and the healthy nerves. Its initial amplitude is a significant indicator of the severity of spinal cord injury.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.
At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
› Verified 3 days ago
| Entity Name | Coastal Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932175684 PECOS PAC ID: 7113029257 Enrollment ID: O20070221000057 |
News Archive
By choosing U.S. Representative Paul Ryan as his running mate, Mitt Romney has added some verve to what had been a tedious presidential contest. ... Now we have the potential at least for a true contest of ideas: What is the optimum size and role of government? What is the best way to reduce trillion-dollar annual deficits and $15 trillion in total debt? With a rapidly graying population and entitlements that eat up most of the federal budget, can Medicare's growth be stopped without impoverishing senior citizens? Is it time to raise taxes, even on the middle class?
An injury potential is the direct current potential difference between the site of spinal cord injury and the healthy nerves. Its initial amplitude is a significant indicator of the severity of spinal cord injury.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.
At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
› Verified 3 days ago
| Entity Name | Marlborough Hospitalist Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316639321 PECOS PAC ID: 1254793888 Enrollment ID: O20230815001157 |
News Archive
By choosing U.S. Representative Paul Ryan as his running mate, Mitt Romney has added some verve to what had been a tedious presidential contest. ... Now we have the potential at least for a true contest of ideas: What is the optimum size and role of government? What is the best way to reduce trillion-dollar annual deficits and $15 trillion in total debt? With a rapidly graying population and entitlements that eat up most of the federal budget, can Medicare's growth be stopped without impoverishing senior citizens? Is it time to raise taxes, even on the middle class?
An injury potential is the direct current potential difference between the site of spinal cord injury and the healthy nerves. Its initial amplitude is a significant indicator of the severity of spinal cord injury.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.
At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yunus Emre Tarhan, MD Po Box 845347, Dallas, TX 75284-7208 Ph: (214) 633-5555 | Yunus Emre Tarhan, MD 6201 Harry Hines Blvd, Dallas, TX 75390-5400 Ph: (214) 633-5555 |
News Archive
By choosing U.S. Representative Paul Ryan as his running mate, Mitt Romney has added some verve to what had been a tedious presidential contest. ... Now we have the potential at least for a true contest of ideas: What is the optimum size and role of government? What is the best way to reduce trillion-dollar annual deficits and $15 trillion in total debt? With a rapidly graying population and entitlements that eat up most of the federal budget, can Medicare's growth be stopped without impoverishing senior citizens? Is it time to raise taxes, even on the middle class?
An injury potential is the direct current potential difference between the site of spinal cord injury and the healthy nerves. Its initial amplitude is a significant indicator of the severity of spinal cord injury.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.
At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
› Verified 3 days ago
Uma B.r.k Pakkivenkata, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 215, Dallas, TX 75231 Phone: 214-396-4950 Fax: 877-423-5360 | |
Dr. Ariel Marcelo Modrykamien, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3600 Gaston Ave, Wadley Tower, Suite 960, Dallas, TX 75246 Phone: 402-972-6078 | |
Benjamin Seth Martinez, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3111 Fax: 214-648-5461 | |
Vijaya Mummadi, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 225, Dallas, TX 75231 Phone: 469-646-8880 Fax: 469-646-8884 | |
Dr. Ting-yi Chen, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2800 Fax: 214-645-2808 | |
William Cook Langmade, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1441 N Beckley Ave, Dallas, TX 75203 Phone: 214-947-2306 | |
Dr. Janame J Kottey, MBBS Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 13154 Coit Rd Ste 100, Dallas, TX 75240 Phone: 214-358-2300 Fax: 214-579-6989 |